Skye acquires Bird Rock Bio, weeks after Novo Nordisk says it will buy a CB1 developer

Skye Bioscience acquired Bird Rock Bio to get its hands on an asset targeting CB1 just two weeks after Novo Nordisk dipped its toes into the once-hot space to buy Inversago Pharma, another developer of CB1 therapies.

The San Diego biotech said Monday morning it…
Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks